JP2008512479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512479A5 JP2008512479A5 JP2007531333A JP2007531333A JP2008512479A5 JP 2008512479 A5 JP2008512479 A5 JP 2008512479A5 JP 2007531333 A JP2007531333 A JP 2007531333A JP 2007531333 A JP2007531333 A JP 2007531333A JP 2008512479 A5 JP2008512479 A5 JP 2008512479A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- medicament according
- death receptor
- receptor
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60783404P | 2004-09-08 | 2004-09-08 | |
| US66655005P | 2005-03-30 | 2005-03-30 | |
| PCT/US2005/032015 WO2006029275A2 (en) | 2004-09-08 | 2005-09-07 | Methods of using death receptor ligands and cd20 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512479A JP2008512479A (ja) | 2008-04-24 |
| JP2008512479A5 true JP2008512479A5 (cg-RX-API-DMAC7.html) | 2008-10-23 |
Family
ID=35788041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531333A Pending JP2008512479A (ja) | 2004-09-08 | 2005-09-07 | デスレセプターリガンド及びcd20抗体の使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090175854A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1802660A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008512479A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070050951A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101048428A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005282397A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0515604A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2577828A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL181315A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20071789L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ553171A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2007112952A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006029275A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| HUE038955T2 (hu) * | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| BRPI0509201A (pt) | 2004-03-23 | 2007-08-28 | Biogen Idec Inc | agentes de acoplamento de receptor e usos terapêuticos destes |
| WO2008066854A2 (en) * | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
| JP5624471B2 (ja) * | 2007-09-24 | 2014-11-12 | バーイラン ユニバーシティー | 磁性金属酸化物で被覆されたポリマー性ナノ粒子及びその使用 |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| JP5950824B2 (ja) | 2009-12-07 | 2016-07-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗腫瘍抗体療法を増強するための方法 |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| CN107250161A (zh) | 2015-01-26 | 2017-10-13 | 宏观基因有限公司 | 包含dr5‑结合结构域的多价分子 |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2023091887A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU704440B2 (en) * | 1994-02-04 | 1999-04-22 | Bio Merieux | MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same |
| CA2225378C (en) * | 1995-06-29 | 2012-04-17 | Immunex Corporation | Cytokine that induces apoptosis |
| US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| ATE362982T1 (de) * | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| NZ508381A (en) * | 1997-03-17 | 2002-09-27 | Human Genome Sciences Inc | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| WO1998046643A1 (en) * | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| PT1053256E (pt) * | 1998-01-26 | 2011-09-28 | Genentech Inc | Anticorpos para o receptor de morte 4 (dr4) e utilizações destes |
| US6252050B1 (en) * | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| CA2439735A1 (en) * | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
| EP1506285B1 (en) * | 2001-11-01 | 2010-12-08 | Uab Research Foundation | Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents |
-
2005
- 2005-09-07 RU RU2007112952/13A patent/RU2007112952A/ru not_active Application Discontinuation
- 2005-09-07 KR KR1020077005375A patent/KR20070050951A/ko not_active Withdrawn
- 2005-09-07 JP JP2007531333A patent/JP2008512479A/ja active Pending
- 2005-09-07 AU AU2005282397A patent/AU2005282397A1/en not_active Abandoned
- 2005-09-07 US US11/662,315 patent/US20090175854A1/en not_active Abandoned
- 2005-09-07 BR BRPI0515604-1A patent/BRPI0515604A/pt not_active IP Right Cessation
- 2005-09-07 CA CA002577828A patent/CA2577828A1/en not_active Abandoned
- 2005-09-07 NZ NZ553171A patent/NZ553171A/en not_active IP Right Cessation
- 2005-09-07 CN CNA2005800364755A patent/CN101048428A/zh active Pending
- 2005-09-07 EP EP05795474A patent/EP1802660A2/en not_active Withdrawn
- 2005-09-07 WO PCT/US2005/032015 patent/WO2006029275A2/en not_active Ceased
-
2006
- 2006-10-03 US US11/542,330 patent/US20070231324A1/en not_active Abandoned
-
2007
- 2007-02-13 IL IL181315A patent/IL181315A0/en unknown
- 2007-04-04 NO NO20071789A patent/NO20071789L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ishii et al. | Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma | |
| JP2008513367A5 (cg-RX-API-DMAC7.html) | ||
| CN107660151B (zh) | 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途 | |
| Yano et al. | Defucosylated anti–CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sézary syndrome | |
| Makita et al. | Mogamulizumab for the treatment of T-cell lymphoma | |
| Beckwith et al. | The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model | |
| JP2014501729A5 (cg-RX-API-DMAC7.html) | ||
| AU7626000A (en) | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies | |
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| JP2008513354A5 (cg-RX-API-DMAC7.html) | ||
| RS62260B1 (sr) | Kombinacije i njihova upotreba | |
| RU2007112952A (ru) | Способы применения лигандов рецепторов смерти и cd20-антител | |
| US20230014026A1 (en) | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint | |
| CN101678101B (zh) | 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物 | |
| Georgakopoulou et al. | Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare | |
| Ishida et al. | Antibody therapy for Adult T-cell leukemia–lymphoma | |
| Shalabi et al. | Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS) | |
| JP2006528627A5 (cg-RX-API-DMAC7.html) | ||
| Xiao et al. | Targeting the CD47-SIRPα axis: Present therapies and the future for cutaneous T-cell lymphoma | |
| US20250074981A1 (en) | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer | |
| CN113613678A (zh) | 使用抗cd30抗体药物缀合物疗法治疗外周t细胞淋巴瘤的方法 | |
| JP2021517144A (ja) | Cd47遮断療法およびcd38抗体の組み合わせ | |
| Stanley et al. | Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infection | |
| Bhandari et al. | Novel applications of Rituximab in dermatological disorders | |
| Tay et al. | Novel agents for B-cell non-Hodgkin lymphoma: science and the promise |